Predicine to Present 15 Liquid Biopsy Studies at AACR 2024

HAYWARD, Calif., April 05, 2024 (GLOBE NEWSWIRE) — Predicine, Inc. A leading precision oncology company, announced today that it will present data from 15 ctDNA studies at AACR 2024, spotlighting the clinical utility of Predicine’s genomic and epigenomic liquid biopsy solutions for patient selection, disease monitoring, and disease mechanism studies. Predicine to Present 15 Liquid Biopsy Studies at AACR 2024